IP Library › Granted Patent US 12,740,888
Granted Patent B2
US 12,740,888 · App. 16/523,078 · Granted Sep 22, 2026

Treatment apparatus and methods

Inventors: Paul Badawi (Menlo Park, CA); Scott Harshman (Woodinville, WA)
Assignee: Sight Sciences, Inc.
A61F7/007A61F2007/0004A61F2007/0086A61F2007/0093
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,740,888
App. No.
16/523,078
Granted
Sep 22, 2026
Kind
B2
Abstract

Treatment apparatus and methods are described for treating the meibomian glands of a subject. The system may generally include a substrate layer having one or more heating elements incorporated, a ductile layer attached in proximity to the substrate layer and configured to conform and retain a shape of the heating strip to an anatomy of an underlying region of skin of an eyelid of a subject, and a protective layer attached in proximity to the ductile layer. The system may further include a controller which is programmable for a treatment therapy and which is in communication with the substrate layer via a connecting cable which transmits electrical energy to the substrate layer which receives the electrical energy and emits thermal energy which is conducted throughout the strip via the ductile layer to the underlying region of skin.

Claims (44)

1 . A heating strip system, comprising:

a substrate layer having one or more heating elements incorporated;

a flexible connector formed from the substrate layer and configured to extend from the substrate layer;

a ductile layer attached in proximity to the substrate layer and configured to conform and retain a shape of the substrate layer to an anatomy of an underlying region of skin of an eyelid of a subject;

a protective layer attached in proximity to the ductile layer and where the protective layer, ductile layer, and substrate layer each has a contour which is identical to one another, where the ductile layer and the protective layer are coextensive with a treatment portion of the substrate layer to define a peripheral boundary of the treatment portion, and where the flexible connector is further configured to extend beyond the peripheral boundary, and where each layer defines an opening at each end and at a central portion away from a proximal edge and a distal edge such that each opening coincides with one another when each layer is aligned upon one another, and where each layer is assembled into a heating strip such that the heating strip presents a flush and smooth surface configured to adhere to the underlying region of skin and where the heating strip has a flexibility sufficient to accommodate movement of the eyelid to allow for the subject to blink naturally without restriction while conforming and retaining its shape to the underlying region via the ductile layer; and

a controller which is programmable for a treatment therapy and which is in communication with the substrate layer via the flexible connector which is configured to transmit electrical energy to the substrate layer which is configured to receive the electrical energy and emit thermal energy for conduction throughout the heating strip via the ductile layer such that the thermal energy is directed inwardly via the protective layer to the underlying region of skin.

2 . The system of claim 1 wherein the heating strip has a first periphery which is shaped to extend and follow a border of one or more meibomian glands contained within the underlying region of skin, and the heating strip further has a second periphery which is shaped to extend and follow a free margin of the eyelid.

3 . The system of claim 2 wherein the heating strip is configured to adhere to an upper eyelid.

4 . The system of claim 3 further comprising a second heating strip in communication with the controller and configured to adhere to a lower eyelid of the subject.

5 . The system of claim 4 wherein the heating strip and second heating strip are electrically coupled to one another via a coupler.

6 . The system of claim 1 wherein the heating strip comprises a contact surface for placement against the underlying region of skin.

7 . The system of claim 1 wherein the controller is programmed to control one or more parameters of the heating strip.

8 . The system of claim 7 wherein the one or more parameters comprise a temperature, treatment time, frequency of treatment, or thermal profile of the heating strip.

9 . The system of claim 7 wherein the controller is programmed to heat the heating strip to a temperature of between 40° to 50° C.

10 . The system of claim 7 wherein the controller is programmed to heat the heating strip to a temperature up to 45° C.

11 . The system of claim 7 wherein the controller is programmed to heat the heating strip to a temperature of between 40.5° to 44.5° C.

12 . The system of claim 7 wherein the controller is programmed to heat the heating strip to a temperature of between 41.5° to 43.5° C.

13 . The system of claim 1 further comprising one or more temperature sensors incorporated into the heating strip for regulating a temperature of the heating strip.

14 . The system of claim 1 wherein the controller is programmed to heat the heating strip for at least between 10 minutes and 60 minutes.

15 . The system of claim 1 wherein the controller is programmed to heat the heating strip for up to 15 minutes.

16 . A method of treating a subject, comprising:

conforming a heating strip to an underlying region of skin of an eyelid of a subject via a ductile layer which conforms and retains its shape within the heating strip such that the heating strip retains a shape of an anatomy of the underlying region of skin, wherein the ductile layer is positioned between a protective layer and a substrate layer and further presents a flush and smooth surface and where the protective layer, ductile layer, and substrate layer each has a contour which is identical to one another, and where the ductile layer and the protective layer are coextensive with a treatment portion of the substrate layer to define a peripheral boundary of the treatment portion, and where each layer defines an opening at each end and at a central portion away from a proximal edge and a distal edge such that the openings coincide with one another when each layer is aligned upon one another;

initiating a treatment with the heating strip via a controller transmitting electrical energy to the substrate layer of the heating strip having one or more heating elements via a flexible connector formed from the substrate layer and configured to extend from the substrate layer, and where the flexible connector is further configured to extend beyond the peripheral boundary of the treatment portion of the substrate layer; and

conducting thermal energy from the substrate layer throughout the heating strip via the ductile layer such that the thermal energy is directed inwardly via the protective layer and into the underlying region of skin.

17 . The method of claim 16 wherein the heating strip has a flexibility sufficient to accommodate movement of the eyelid to allow for the subject to blink naturally without restriction from the heating strip while covering one or more meibomian glands contained within the eyelid with the heating strip.

18 . The method of claim 17 wherein the heating strip has a first periphery which is shaped to extend and follow a border of the one or more meibomian glands contained within the eyelid and a second periphery which is shaped to extend and follow a free margin of the eyelid.

19 . The method of claim 16 wherein conforming the heating strip comprises adhering the heating strip to an upper eyelid of the subject.

20 . The method of claim 19 further comprising adhering a second strip to a lower eyelid of the subject such that one or more meibomian glands contained within the lower eyelid are covered by the second strip.

21 . The method of claim 20 wherein the heating strip and the second strip are electrically coupled to one another.

22 . The method of claim 16 wherein initiating the treatment comprises programming the heating strip via the controller attached to the substrate layer.

23 . The method of claim 22 wherein programming the heating strip comprises controlling one or more parameters of the heating strip.

24 . The method of claim 23 wherein controlling the one or more parameters comprises controlling a temperature, treatment time, frequency of treatment, or thermal profile of the heating strip.

25 . The method of claim 23 wherein controlling the one or more parameters comprises heating the heating strip to a temperature of between 40° to 50° C.

26 . The method of claim 23 wherein controlling the one or more parameters comprises heating the heating strip to a temperature up to 45° C.

27 . The method of claim 23 wherein controlling the one or more parameters comprises heating the heating strip to a temperature of between 40.5° to 44.5° C.

28 . The method of claim 23 wherein controlling the one or more parameters comprises heating the heating strip to a temperature of between 41.5° to 43.5° C.

29 . The method of claim 16 wherein the method of treating comprises treating one or more conditions selected from the group consisting of dry eye, evaporative dry eye, and Meibomian gland dysfunction.

30 . The method of claim 16 wherein the method of treating comprises treating to improve one or more conditions selected from the group consisting of an ocular surface inflammation, degraded tear quality, degraded lipid layer of tears, and shortened tear break up time.

31 . The method of claim 16 further comprising monitoring a temperature of the heating strip via one or more temperature sensors incorporated into the heating strip.

32 . The method of claim 16 wherein conducting thermal energy comprises heating the heating strip for at least between 10 minutes and 60 minutes.

33 . The method of claim 16 wherein conducting thermal energy comprises heating the heating strip for up to 15 minutes.

34 . The method of claim 16 wherein the method comprises treating the subject for a condition selected from the group consisting of meibomitis, blepharitis, ocular rosacea, acne, arthralgia, myalgia, hordeolum, styes, chalazion, and abcesses.

35 . The method of claim 16 wherein the method comprises treating the subject for a condition selected from the group consisting of conjunctivitis, keratitis, keratopathy, iritis, cyclitis, glaucoma, and cataract.

36 . The method of claim 16 wherein the method comprises treating the subject for improving a comfort level for wearing a contact lens.

Assignments (2)
SECURITY INTEREST Recorded Jan 23, 2024
From: SIGHT SCIENCES, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 066364/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: BADAWI, PAUL; HARSHMAN, SCOTT
To: SIGHT SCIENCES, INC.
Reel/Frame 051179/0319 →
Continuity (1)
Related Publication 20210022914A1 · Jan 28, 2021
References Cited (236)
US 2001862A · Carter · 1935 [cited by applicant]
US 2108934A · Albright · 1938 [cited by applicant]
US 2635175A · Hodge · 1953 [cited by applicant]
US 3075527A · Bechtold · 1963 [cited by applicant]
US 3173419A · Dublier et al. · 1965 [cited by applicant]
US 3589369A · Alksnis · 1971 [cited by applicant]
US 4096864A · Kletschka et al. · 1978 [cited by applicant]
US 4261364A · Haddad et al. · 1981 [cited by applicant]
US 4325254A · Svacina et al. · 1982 [cited by applicant]
US 4867146A · Krupnick et al. · 1989 [cited by applicant]
US 4930317A · Klein · 1990 [cited by applicant]
US 4962761A · Golden · 1990 [cited by applicant]
US 5097829A · Quisenberry · 1992 [cited by applicant]
US 5164987A · Raven · 1992 [cited by applicant]
US 5169384A · Bosniak et al. · 1992 [cited by applicant]
US 5643336A · Lopez-Claros · 1997 [cited by applicant]
US 5860985A · Anschutz · 1999 [cited by applicant]
US 6066164A · Macher et al. · 2000 [cited by applicant]
US 6074414A · Haas et al. · 2000 [cited by applicant]
US 6155995A · Lin · 2000 [cited by applicant]
US 6193741B1 · Heavenridge et al. · 2001 [cited by applicant]
US D441081S · Mueller · 2001 [cited by applicant]
US 6238427B1 · Matta · 2001 [cited by applicant]
US 6409746B1 · Igaki et al. · 2002 [cited by applicant]
US 6416534B1 · Montagnino et al. · 2002 [cited by applicant]
US 6511446B1 · Wu · 2003 [cited by applicant]
US 6860880B2 · Treat et al. · 2005 [cited by applicant]
US 6908195B2 · Fuller, Jr. · 2005 [cited by applicant]
US D507054S · Mueller et al. · 2005 [cited by applicant]
US D507055S · Mueller et al. · 2005 [cited by applicant]
US D507350S · Mueller et al. · 2005 [cited by applicant]
US D507651S · Mueller et al. · 2005 [cited by applicant]
US 6923988B2 · Patel et al. · 2005 [cited by applicant]
US D511573S · Mueller et al. · 2005 [cited by applicant]
US D513323S · Mueller et al. · 2005 [cited by applicant]
US 7069084B2 · Yee · 2006 [cited by applicant]
US 7108694B2 · Miura et al. · 2006 [cited by applicant]
US 7211070B2 · Soroudi · 2007 [cited by applicant]
US 7229468B2 · Wong, Jr. et al. · 2007 [cited by applicant]
US D613408S · Gausmann et al. · 2010 [cited by applicant]
US D614303S · Gausmann et al. · 2010 [cited by applicant]
US D614774S · Gausmann et al. · 2010 [cited by applicant]
US D617443S · Grenon et al. · 2010 [cited by applicant]
US 7758190B2 · Korb et al. · 2010 [cited by applicant]
US 7833205B2 · Grenon et al. · 2010 [cited by applicant]
US D638128S · Prokop et al. · 2011 [cited by applicant]
US 7976573B2 · Korb et al. · 2011 [cited by applicant]
US 7981095B2 · Grenon et al. · 2011 [cited by applicant]
US 7981145B2 · Korb et al. · 2011 [cited by applicant]
US 7981146B2 · Korb et al. · 2011 [cited by applicant]
US 7981147B2 · Korb et al. · 2011 [cited by applicant]
US 7988294B2 · Korb et al. · 2011 [cited by applicant]
US 8007524B2 · Korb et al. · 2011 [cited by applicant]
US 8025689B2 · Korb et al. · 2011 [cited by applicant]
US 8506539B2 · Guillon et al. · 2013 [cited by applicant]
US 8535363B1 · Lewis · 2013 [cited by applicant]
US 8685073B2 · Korb et al. · 2014 [cited by applicant]
US 8915253B2 · Grenon et al. · 2014 [cited by applicant]
US 8950405B2 · Grenon et al. · 2015 [cited by applicant]
US 8960204B2 · Samain et al. · 2015 [cited by applicant]
US 9510972B2 · Badawi · 2016 [cited by applicant]
US 9642743B2 · Badawi · 2017 [cited by applicant]
US 9724230B2 · Badawi · 2017 [cited by applicant]
US 9844459B2 · Badawi · 2017 [cited by applicant]
US 10052226B2 · Badawi et al. · 2018 [cited by applicant]
US 10772758B2 · Badawi · 2020 [cited by applicant]
US 10925765B2 · Badawi · 2021 [cited by applicant]
US 10973680B2 · Badawi et al. · 2021 [cited by applicant]
US 11285040B2 · Badawi et al. · 2022 [cited by applicant]
US 12257181B2 · Badawi et al. · 2025 [cited by applicant]
US 12263115B2 · Badawi et al. · 2025 [cited by applicant]
US 12336930B2 · Badawi · 2025 [cited by applicant]
US 20020117495A1 · Kochman et al. · 2002 [cited by applicant]
US 20020180929A1 · Tseng et al. · 2002 [cited by applicant]
US 20030167556A1 · Kelley · 2003 [cited by applicant]
US 20030236487A1 · Knowlton · 2003 [cited by applicant]
US 20040044384A1 · Leber · 2004 [cited by examiner]
US 20040116990A1 · Agarwal et al. · 2004 [cited by applicant]
US 20040237969A1 · Fuller · 2004 [cited by applicant]
US 20050119629A1 · Soroudi · 2005 [cited by applicant]
US 20050159775A1 · Reynolds · 2005 [cited by applicant]
US 20050187502A1 · Krempel et al. · 2005 [cited by applicant]
US 20060018953A1 · Guillon et al. · 2006 [cited by applicant]
US 20060069420A1 · Rademacher et al. · 2006 [cited by applicant]
US 20060136022A1 · Wong et al. · 2006 [cited by applicant]
US 20060154642A1 · Scannell · 2006 [cited by applicant]
US 20060200052A1 · Lin · 2006 [cited by applicant]
US 20060219701A1 · Kil · 2006 [cited by applicant]
US 20060235497A1 · Zanotti · 2006 [cited by applicant]
US 20070016255A1 · Korb et al. · 2007 [cited by applicant]
US 20070060988A1 · Grenon et al. · 2007 [cited by applicant]
US 20070282012A1 · Kinoshita et al. · 2007 [cited by applicant]
US 20080039749A1 · Kopanic et al. · 2008 [cited by applicant]
US 20080039769A1 · Peyman · 2008 [cited by applicant]
US 20080081999A1 · Gravely et al. · 2008 [cited by applicant]
US 20080109053A1 · Grenon et al. · 2008 [cited by applicant]
US 20080114421A1 · Korb et al. · 2008 [cited by applicant]
US 20080114423A1 · Grenon et al. · 2008 [cited by applicant]
US 20080114424A1 · Grenon et al. · 2008 [cited by applicant]
US 20080132978A1 · Korb et al. · 2008 [cited by applicant]
US 20080132987A1 · Westlund et al. · 2008 [cited by applicant]
US 20080269850A1 · Dodo · 2008 [cited by applicant]
US 20090020521A1 · Blaszczykiewicz et al. · 2009 [cited by applicant]
US 20090048590A1 · Conrad et al. · 2009 [cited by applicant]
US 20090123886A1 · Vaska · 2009 [cited by applicant]
US 20090137533A1 · Adkins, Jr. · 2009 [cited by applicant]
US 20090149925A1 · MacDonald et al. · 2009 [cited by applicant]
US 20090168019A1 · Tuan · 2009 [cited by applicant]
US 20090199571A1 · Creech et al. · 2009 [cited by applicant]
US 20090312823A1 · Patience et al. · 2009 [cited by applicant]
US 20100010598A1 · Igaki et al. · 2010 [cited by applicant]
US 20100114086A1 · Deem et al. · 2010 [cited by applicant]
US 20100172567A1 · Prokoski · 2010 [cited by applicant]
US 20100174501A1 · Myadam · 2010 [cited by applicant]
US 20100198282A1 · Rogers · 2010 [cited by applicant]
US 20100217360A1 · Henriksson et al. · 2010 [cited by applicant]
US 20100267751A1 · Beals et al. · 2010 [cited by applicant]
US 20100286654A1 · Dos Santos et al. · 2010 [cited by applicant]
US 20110046581A1 · Linder · 2011 [cited by applicant]
US 20110081333A1 · Shantha et al. · 2011 [cited by applicant]
US 20110198282A1 · Chu et al. · 2011 [cited by applicant]
US 20110275410A1 · Caffey et al. · 2011 [cited by applicant]
US 20120062840A1 · Ballou et al. · 2012 [cited by applicant]
US 20120191164A1 · Gander et al. · 2012 [cited by applicant]
US 20120213840A1 · Lim · 2012 [cited by applicant]
US 20120222192A1 · Carey et al. · 2012 [cited by applicant]
US 20130046367A1 · Chen · 2013 [cited by applicant]
US 20130083184A1 · Yogesan et al. · 2013 [cited by applicant]
US 20130172790A1 · Badawi · 2013 [cited by applicant]
US 20130172829A1 · Badawi · 2013 [cited by applicant]
US 20130281893A1 · Yang · 2013 [cited by applicant]
US 20130288196A1 · Gordon · 2013 [cited by applicant]
US 20140052198A1 · Mohn · 2014 [cited by examiner]
US 20140276248A1 · Hall et al. · 2014 [cited by applicant]
US 20140303694A1 · Timme et al. · 2014 [cited by applicant]
US 20140316314A1 · Schubert · 2014 [cited by applicant]
US 20140330129A1 · Grenon et al. · 2014 [cited by applicant]
US 20150024339A1 · Calderon · 2015 [cited by applicant]
US 20150025545A1 · Grenon et al. · 2015 [cited by applicant]
US 20150202417A1 · Abreu · 2015 [cited by applicant]
US 20150216725A1 · Badawi et al. · 2015 [cited by applicant]
US 20160045755A1 · Chun et al. · 2016 [cited by applicant]
US 20160100977A1 · Lee · 2016 [cited by examiner]
US 20160106576A1 · Badawi et al. · 2016 [cited by applicant]
US 20160106775A1 · Alster et al. · 2016 [cited by applicant]
US 20160317379A1 · Mosaddegh · 2016 [cited by applicant]
US 20170014300A1 · Dippo · 2017 [cited by examiner]
US 20170079834A1 · Badawi · 2017 [cited by applicant]
US 20170079840A1 · Badawi · 2017 [cited by applicant]
US 20170087009A1 · Badawi et al. · 2017 [cited by applicant]
US 20170165106A1 · Badawi · 2017 [cited by applicant]
US 20170188805A1 · Pradeep · 2017 [cited by applicant]
US 20170273823A1 · Novkov et al. · 2017 [cited by applicant]
US 20170304110A1 · Badawi · 2017 [cited by applicant]
US 20180060556A1 · Fujino · 2018 [cited by applicant]
US 20180071140A1 · Sheydin · 2018 [cited by examiner]
US 20180200494A1 · Gatrall et al. · 2018 [cited by applicant]
US 20180344512A1 · Badawi · 2018 [cited by applicant]
US 20190274873A1 · Schoeggler · 2019 [cited by examiner]
US 20200078032A1 · Nanda et al. · 2020 [cited by applicant]
US 20200078211A1 · Badawi et al. · 2020 [cited by applicant]
US 20200188169A1 · McMahon · 2020 [cited by applicant]
US 20210052216A1 · Badawi · 2021 [cited by applicant]
US 20210128058A1 · Habib · 2021 [cited by applicant]
US 20210169682A1 · Alvarez · 2021 [cited by examiner]
US 20210177647A1 · Badawi · 2021 [cited by applicant]
US 20210177648A1 · Badawi et al. · 2021 [cited by applicant]
US 20220168136A1 · Badawi et al. · 2022 [cited by applicant]
US 20230079255A1 · DeAyala · 2023 [cited by applicant]
US 20240238119A1 · Takakuwa · 2024 [cited by applicant]
US 20250177198A1 · Badawi et al. · 2025 [cited by applicant]
US 20250228702A1 · Badawi · 2025 [cited by applicant]
US 20250288458A1 · Badawi · 2025 [cited by applicant]
US 20250352055A1 · Park et al. · 2025 [cited by applicant]
US 20250352059A1 · Park et al. · 2025 [cited by applicant]
US 20260130791A1 · Badawi et al. · 2026 [cited by applicant]
CN 202313590 · 2012 [cited by applicant]
CN 103417306 · 2013 [cited by applicant]
CN 203493672 · 2014 [cited by applicant]
CN 203564408 · 2014 [cited by applicant]
CN 205234758 · 2016 [cited by applicant]
CN 205568977 · 2016 [cited by applicant]
CN 107510545 · 2017 [cited by applicant]
DE 29920352 · 2000 [cited by applicant]
JP 1995185017 · 1995 [cited by applicant]
JP 3071816 · 2000 [cited by applicant]
JP 2003093431 · 2003 [cited by applicant]
JP 2007000520 · 2007 [cited by applicant]
JP 2007185017 · 2007 [cited by applicant]
JP 2007229175 · 2007 [cited by applicant]
JP 3170844 · 2011 [cited by applicant]
JP 2015503417 · 2015 [cited by applicant]
JP 2015527122 · 2015 [cited by applicant]
JP 2016522711 · 2016 [cited by applicant]
JP 2017533074 · 2017 [cited by applicant]
JP 2020199386 · 2020 [cited by applicant]
KR 200301311 · 2003 [cited by applicant]
KR 20100002818 · 2010 [cited by applicant]
WO WO1994011739 · 1994 [cited by applicant]
WO WO1999020213 · 1999 [cited by applicant]
WO WO2000069506 · 2000 [cited by applicant]
WO WO2002067688 · 2002 [cited by applicant]
WO WO2004006801 · 2004 [cited by applicant]
WO WO2005067907 · 2005 [cited by applicant]
WO WO2006099413 · 2006 [cited by applicant]
WO WO2007102362 · 2007 [cited by applicant]
WO WO2008085162 · 2008 [cited by applicant]
WO WO2008100647 · 2008 [cited by applicant]
WO WO2011116306 · 2011 [cited by applicant]
WO WO2013103413 · 2013 [cited by applicant]
WO WO2016070134 · 2016 [cited by applicant]
WO WO2017100608 · 2017 [cited by applicant]
WO WO2018156022 · 2018 [cited by applicant]
WO WO2020055634 · 2019 [cited by applicant]
WO WO2021026154 · 2021 [cited by applicant]
WO WO2025239981 · 2025 [cited by applicant]
Blackie, Caroline A. et al., “Inner Eyelid Surface Temperature as a Function of Warm Compress Methodology,” [cited by applicant]
Bron, A.J. et al., “Functional Aspects of the Tear Film Lipid Layer,” [cited by applicant]
Driver, Paul J. et al., “Meibomian Gland Dysfunction,” [cited by applicant]
Gifford, Sanford R., “Meibomian Glands in Chronic Blepharo-Conjunctivitis,” [cited by applicant]
Goto, E et al., “Treatment of Non-Inflamed Obstructive Meibomian Gland Dysfunction by an Infrared Warm Compression Device,” [cited by applicant]
Olson, Mary Catherine et al., “Increase in Tear Film Lipid Layer Thickness Following Treatment with Warm Compresses in Patients with Meibomian Gland Dysfunction,” [cited by applicant]
Ong, Bee-Leng, “Clinical Diagnosis and Management of Meibomian Gland Dysfunction,” [cited by applicant]
U.S. Appl. No. 13/343,407, filed Jan. 4, 2012. [cited by applicant]
U.S. Appl. No. 13/645,985, filed Oct. 5, 2012. [cited by applicant]
U.S. Appl. No. 14/967,116, filed Dec. 11, 2015. [cited by applicant]
U.S. Appl. No. 15/364,070, filed Nov. 29, 2016. [cited by applicant]
U.S. Appl. No. 15/369,176, filed Dec. 5, 2016. [cited by applicant]
U.S. Appl. No. 15/374,426, filed Dec. 9, 2016. [cited by applicant]
U.S. Appl. No. 15/442,003, filed Feb. 24, 2017. [cited by applicant]
U.S. Appl. No. 15/639,850, filed Jun. 30, 2017. [cited by applicant]
U.S. Appl. No. 16/059,281, filed Aug. 9, 2018. [cited by applicant]
U.S. Appl. No. 16/127,870, filed Sep. 11, 2018. [cited by applicant]
Leahy-Smith America Invents Act, H.R.1249, 112th Cong. (2011), https://www.congress.gov/bill/112th-congress/house-bill/1249 H.R. 1249—112th Congress (2011-2012). [cited by applicant]
Lee, Jeanette, OD shares drug-free approach to treating meibomian gland dysfunction, https://www.healio.com/news/optometry/20120225/od-shares-drug-free-approach-to-treating-meibomian-gland-dysfunction, published: Nov. 1… [cited by applicant]
ZDNET, Why you need an Android smartphone with a thermal and IR camera. Jun. 22, 2022. Retrieved from the Internet May 7, 2025. [https://www.zdnet.com/article/why-you-need-anandroid-smartphone-with-a-thermal-and-ir-came… [cited by applicant]